Summary
The Multiple Risk Factor Intervention Trial was a long term study on the benefit of lowering risk factors for coronary heart disease mortality in middle-aged men. Study participants were randomised to either ‘special intervention’ or ‘usual care’. Intensive intervention for special intervention men involved cholesterol lowering dietary advice, behaviour modification for cigarette smoking and a stepped care pharmacological approach to lower blood pressure.
Overall, at 6 years, there was a 7.1% lower coronary heart disease mortality in special intervention compared with usual care men, a statistically non-significant difference (Confidence Interval +25 to −15%). Subgroup analysis revealed that special intervention men who were hypertensive at baseline and who had resting ECG abnormalities experienced a higher coronary heart disease mortality than the comparable usual care group. Within group Cox regression analysis, with coronary heart disease mortality as the dependent variable, revealed an interaction between diuretic use and resting ECG abnormalities in special intervention men. Additional analyses of clinics revealed a higher special intervention/usual care mortality in those clinics that used mainly hydrochlorothiazide in special intervention hypertensives. Results of the Multiple Risk Factor Intervention Trial raise important questions concerning the treatment of mild hypertension, and the clinical significance of metabolic alterations of antihypertensive drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bartsch GE, Broste SK, Grandits GA, et al. Hydrochlorothiazide, chlorthalidone and mortality in the Multiple Risk Factor Intervention Trial. Circulation 70: 1438, 1984
Cohen JD, Grimm RH, Smith WM. The Multiple Risk Factor Intervention Trial (MRFIT): VI. Intervention on blood pressure. Preventative Medicine 10: 501–508, 1981
Cutler JA, Neaton JD, Kuller L, et al. Coronary heart disease and all cause mortality in the Multiple Risk Factor Intervention Trial: subgroup findings and comparisons with other trials. Preventative Medicine, in press 1985
Fries ED. Should mild hypertension be treated? New England Journal of Medicine 307: 305, 1982
Grimm RH, Leon A, Hunninghake D, et al. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. Annals of Internal Medicine 94: 7–11, 1981
Grimm RH. Should mild hypertension be treated? Early intervention. Medical Clinics of North America 68: 477–489, 1984
HDFP (Hypertension Detection and Follow-up Program Co-operative Group). Five-year findings of the Hypertension Detection and Follow-up Program. I. Reduction in mortality in persons with high blood pressure, including mild hypertension. Journal of the American Medical Association 242: 2562–2571, 1979a
HDFP (Hypertension Detection and Follow-up Program Cooperative Group). Five-year findings of the Hypertension Detection and Follow-up Program. II. Mortality by race, sex and age. Journal of the American Medical Association 242: 2572–2577, 1979b
HDFP (Hypertension Detection and Follow-up Program Cooperative Group). Five-year findings of the Hypertension Detection and Follow-up Program. III. Reduction in stroke incidence among persons with high blood pressure. Journal of the American Medical Association 247: 633–638, 1982a
HDFP (Hypertension Detection and Follow-up Program Cooperative Group). The effect of treatment on mortality in ‘mild’ hypertension. Results of the Hypertension Detection and Follow-up Program. New England Journal of Medicine 307: 976–890, 1982b
Hjermann I, Byre K, Holme I, et al. Effect of diet and smoking intervention on the incidence of coronary heart disease, report from the Oslo Study group of a randomized trial in healthy men. Lancet 2: 1303–1310, 1981
Kaplan NM. Therapy for mild hypertension: toward a more balanced view. Journal of the American Medical Association 249: 365, 1983
Lasser NL, Grandits G, Caggiula AW, et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. American Journal of Medicine 76(2A): 52–66, 1984
McAlister NH. Should we treat ‘mild’ hypertension? Journal of the American Medical Association 249: 379, 1983
MRC (Medical Research Council). Medical Research Council Working Party on mild to moderate hypertension: randomized controlled trial of treatment for mild hypertension. Design and pilot trial. British Medical Journal 1: 1437–1440, 1977
MRFIT (Multiple Risk Factor Intervention Trial Preventative Medicine Research Group). Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. Journal of the American Medical Association 248: 1465–1477, 1982
MRFIT (Multiple Risk Factor Intervention Trial Preventative Medicine Research Group). Exercise electrocardiogram and coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. American Journal of Cardiology 55: 16–23, 1985a
MRFIT (Multiple Risk Factor Intervention Trial Preventative Medicine Research Group). Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. American Journal of Cardiology 55: 1–5, 1985b
Ram CVS. Should mild hypertension be treated? Choosing the middle course. Medical Clinics of North America 68: 469–476, 1984
Report by the Management Committee. The Australian Therapeutic Trial in Mild Hypertension. Lancet 1: 126–267, 1980
Author information
Authors and Affiliations
Additional information
Dr Grimm Jr is an established investigator of the American Heart Association.
Rights and permissions
About this article
Cite this article
Grimm, R.H. The Drug Treatment of Mild Hypertension in the Multiple Risk Factor Intervention Trial. Drugs 31 (Suppl 1), 13–21 (1986). https://doi.org/10.2165/00003495-198600311-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198600311-00005